Updates are available Correction dated 2024-05-02
Click to view Correction: https://doi.org/10.1007/s40262-024-01378-z
-
Authors
Bevers, Lisanne A. H. https://orcid.org/0009-0004-3699-2993
Kamphuis, Anne E. M.
van der Wekken-Pas, L. C. Wendy
Leisegang, Rory
Burger, David M.
Colbers, Angela
-
Funding
Funding for this research was provided by:
Gilead UK and Ireland Corporate Contributions
- License Information
-
More Information
Article History
Accepted: 26 February 2024
First Online: 4 April 2024
Change Date: 2 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40262-024-01378-z
Declarations
:
: Trial medication (F/TAF TOS) was provided, and the trial funded, by Gilead Sciences, Inc. This study was conducted as an addendum to the EDCTP2-funded UNIVERSAL project (RIA2019PD-2882).
: AC and DB have received research grants (paid to the institution) from ViiV Healthcare, Gilead Sciences, and Merck. All other authors have no conflicts of interest to disclose.
: Yes.
: Yes.
: Yes.
: The data that support the findings of this study are available on request from the corresponding author.
: Not applicable.
: LB and AC have written the protocol. LB and AK arranged all study preparations, including recruiting participants. LW was the study physician and did the screening of the participants and had overall medical responsibility. LB and AK processed the samples during the study and were the main contacts during the study days. LB and AK performed the analysis of the study. LB, AK, AC, DB, and RL took part in all substantive discussions. LB and AK wrote the manuscript. All co-authors reviewed the manuscript and provided substantial input that led to the final manuscript.
